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rrelevance of the
hromosome 9p21.3 Locus
or Acute Cardiovascular
vents and Restenosis*
enjamin D. Horne, PHD, MPH,†‡
effrey L. Anderson, MD†§
alt Lake City, Utah
he study of the genetic basis of common complex disease
e.g., coronary heart disease [CHD]) is of scientific interest
or multiple reasons (1,2), including understanding disease
athogenesis, predicting disease risk, and developing new
herapies (e.g., statins were developed after the discovery
hat primary familial hypercholesterolemia arose from mu-
ations in LDLR). Not associated with established risk
See page 1149
actors (3), the chromosome 9p21.3 locus represents a new
enetic risk factor for CHD. This locus was identified by
ultiple genome-wide association studies (GWAS) in 2007
4,5) and has been replicated in dozens of subsequent
tudies (3,6,7). It is located in a chromosomal region devoid
f traditional genes but resides at the site of CDKN2BAS, an
nti-sense noncoding ribonucleic acid (RNA) (also com-
only known as ANRIL) (3).
linical Risk Prediction
lthough 9p21.3 might eventually provide new insights into
he pathogenesis of atherosclerosis or provide a new drug
arget, the present clinical question is whether it is useful in
linical CHD risk prediction and, if so, for which subphe-
otypes (e.g., native coronary artery disease [CAD], myo-
ardial infarction [MI], death, and/or restenosis). When
pplied to clinical risk prediction, genetic factors will require
dditional resource use, including physician and staff edu-
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the †Cardiovascular Department, Intermountain Medical Center, Salt Lake
ity, Utah; and the ‡Genetic Epidemiology Division, Department of BiomedicalC
nformatics, and the §Cardiology Division, Department of Internal Medicine,
niversity of Utah, Salt Lake City, Utah.ation, physicians’ clinic time, and laboratory diagnostics.
ith biotechnology firms eager to launch genetic testing
nto the clinical arena, cost-benefit assessments are critical,
ut such calculations cannot be performed until the value for
isk assessment is determined.
Unfortunately, initial GWAS and most subsequent rep-
ications of 9p21.3 single nucleotide polymorphisms (SNPs)
valuated cases where the majority had experienced MI and
ompared them with control subjects who were population
ormal subjects with no evidence of CHD (3–5). Although
ot an incorrect or valueless design, this comparison evalu-
tes a complex of multiple subphenotypes within both cases
including MI and CAD) and control subjects (i.e., those
ith and without subclinical CAD).
Especially in the clinical arena, the phenotype that a
enetic factor associates with must be precise and accurate
o enable meaningful risk assessment and medical decision-
aking. For example, the occurrence of acute MI requires
he presence of some degree of coronary atherosclerosis
except in rare cases involving atypical mechanisms such as
oronary dissection, embolism, or spasm). Beyond CAD,
owever, MI specifically requires acute precipitating mech-
nisms, including endothelial erosion or plaque rupture and
uperimposed intracoronary thrombosis, regardless of the
egree of coronary stenosis (8,9). Coronary artery disease
part from MI, in contrast, involves initiation and expansion
f atherosclerotic plaques, a decades-long chronic and often
ubclinical process. Restenosis, an iatrogenic lesion that
hares some common features with CAD, also has a distinct
roliferative pathophysiology (10).
The question, then, is: What specific clinical and patho-
ogical phenotypes do SNPs at chromosome 9p21.3 actually
redict?
HD Phenotypes
n bringing crucial information to bear to address this
mportant question, Hoppmann et al. (11), in this issue of
ACC: Cardiovascular Interventions, are to be congratulated.
heir study reports the results of 9p21.3 SNP associations
ith the incidence of the composite end point of death, MI,
r target lesion revascularization (i.e., clinical restenosis)
mong a CAD population during longitudinal observation
ollowing coronary revascularization with drug-eluting
tents. The pathophysiologically-precise end point of angio-
raphic in-segment restenosis could be addressed given
outine angiography at 6 to 8 months.
The study found that the composite primary end point,
ach event individually, and stent thrombosis were not
redicted by 9p21.3 SNPs. Hence, by exclusion in the
resent study and by previous demonstration, 9p21.3 seems
o specifically mark the risk of intrinsic atherosclerotic
laque development (and not the extent of CAD or acute
HD events) (11,12). Furthermore and uniquely, it dem-
o
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1157nstrates that restenosis after stenting is pathophysiologi-
ally distinct from CAD, because it is not driven by genetic
actors at 9p21.3.
The negative genetic association results by Hoppmann et
l. (11) might be puzzling to some who have become accus-
omed to the excessively low p values and uncharacteristically
onsistent 9p21.3 findings in CHD. Confounding by some
ndescribed pharmacogenetic effect of drug-eluting stents
annot be ruled out. More likely, however, the apparent
iscrepancy simply highlights the critical importance of phen-
oype definition. Hoppmann et al. (11), in contrast to most
rior investigators: 1) evaluated control subjects who all suf-
ered from clinically significant CAD; and 2) assessed the
mpact of 9p21.3 on coronary events. Their study included no
ngiographically normal control subjects but rather evaluated
AD patients who, after stenting, did or did not suffer various
linical and angiographic end points over 6 months to 3 years.
hese points cannot be overstated, if genetic research results
re to be used clinically.
Without a clear clinical definition of specific phenotype,
redictive genetics is of little clinical value. Clinical genetic
esting will require, in addition to significant epidemiologic
ssociations, appropriate levels of sensitivity, specificity,
ositive predictive value, and negative predictive value—all
f which operate explicitly on the phenotype definition for
oth affected and unaffected status. Additionally, only a few
tudies have modeled patient risk reclassification by 9p21.3
o evaluate potential clinical utility (6,7). Cost-benefit data
nd the investigation of improvement in outcomes (e.g.,
ower CHD incidence) in actual practice are also necessary
or diagnostic or prognostic application.
The biological pathway influenced by 9p21.3 is unknown.
he investigation of its biological effects might substantively
ugment the understanding of the pathophysiology of ath-
rosclerosis. According to Hirschorn (13), this aim is the
rimary purpose of GWAS. Such contribution to biological
nderstanding, however, is also contingent on a clear
dentification of which phenotype 9p21.3 actually predicts.
f the risk pathway is through plaque erosion, rupture, or
hrombosis, for example, then biological investigation of
p21.3 as a predictor of MI pathogenesis is appropriate.
ecause Hoppmann et al. (11) and Horne et al. (12) have
ound evidence indicating otherwise, efforts to investigate
he biology of MI or restenosis with 9p21.3 might be
is-directed, as might be the search for pharmaceutical
gents that target its (RNA?) product. Rather, a renewed
earch for genetic factors predisposing to these distinct
rocesses is indicated.
onclusions
linical testing of the 9p21.3 SNPs at the present time
emains “recreational genomics” (as Dr. David Goldstein
14] described direct-to-consumer testing), because of the issues relating to the definition of CHD (14). Before clinical
pplication of genetic risk prediction in cardiology, further
efinement and testing of the locus versus specific clinical
henotypes will be required. GWAS of greater sample sizes
nd studies of rare variants also are important (13,15), but
henotype clarity should also be a foremost consideration.
stablished primary and secondary prevention measures
ontinue to represent best care and should include efforts to
aximize adherence to a healthy lifestyle and appropriate
edical interventions.
eprint requests and correspondence: Dr. Benjamin D. Horne,
ardiovascular Department, Intermountain Medical Center, 5121
outh Cottonwood Street, Salt Lake City, Utah 84107. E-mail:
enjamin.horne@imail.org.
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